Bioreductive prodrug; activated by hypoxia to yield the topoisomerase II inhibitor AQ4. Displays little to no cytotoxic activity against 60 tumor cell lines tested under oxic conditions (IC50
M). Exhibits anti-tumor efficacy in vivo
when combined with oxic cell cytotoxins; enhances the anti-tumor effect of cyclophosphamide
(Cat. No. 4091) in a mouse tumor model.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine.
Friery et al.
AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson and McKeown
Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
Mehibel et al.
Mol.Cancer Ther., 2009;8:1261